OBJECTIVE: To assess the relationship between plasma nevirapine concentrations and plasma HIV-1 RNA response in HIV-1-infected patients. DESIGN: An observational cohort analysis. METHODS: Plasma samples were obtained on a routine basis from 189 patients receiving nevirapine 200mg twice daily, and plasma nevirapine concentrations were measured with reversed phase high performance liquid chromatography. Patients were divided into two groups based on plasma nevirapine concentrations below (and equal to) or above 3 mg/L. The association between steady-state nevirapine concentrations and plasma HIV-1 RNA was determined by multivariate analysis. RESULTS: Out of 189 patients, 13 (7%) had low nevirapine plasma concentrations and 176 patients had concentrations above 3 mg/L. In total, 22 (12%) patients showed virological failure and 8 patients (4%) discontinued nevirapine because of adverse effects. The risk of failure in patients with nevirapine plasma concentrations </=3mg/L was increased (relative risk 5.0, 95% CI 1.8-13.7). Rashes and liver enzyme elevations each occurred in 8% of patients. CONCLUSIONS: Low nevirapine drug concentrations are predictive of virological failure.
OBJECTIVE: To assess the relationship between plasma nevirapine concentrations and plasma HIV-1 RNA response in HIV-1-infectedpatients. DESIGN: An observational cohort analysis. METHODS: Plasma samples were obtained on a routine basis from 189 patients receiving nevirapine 200mg twice daily, and plasma nevirapine concentrations were measured with reversed phase high performance liquid chromatography. Patients were divided into two groups based on plasma nevirapine concentrations below (and equal to) or above 3 mg/L. The association between steady-state nevirapine concentrations and plasma HIV-1 RNA was determined by multivariate analysis. RESULTS: Out of 189 patients, 13 (7%) had low nevirapine plasma concentrations and 176 patients had concentrations above 3 mg/L. In total, 22 (12%) patients showed virological failure and 8 patients (4%) discontinued nevirapine because of adverse effects. The risk of failure in patients with nevirapine plasma concentrations </=3mg/L was increased (relative risk 5.0, 95% CI 1.8-13.7). Rashes and liver enzyme elevations each occurred in 8% of patients. CONCLUSIONS: Low nevirapine drug concentrations are predictive of virological failure.
Authors: R P van Heeswijk; A I Veldkamp; J W Mulder; P L Meenhorst; F W Wit; J M Lange; S A Danner; N A Foudraine; M O Kwakkelstein; P Reiss; J H Beijnen; R M Hoetelmans Journal: AIDS Date: 2000-05-26 Impact factor: 4.177
Authors: A I Veldkamp; R P van Heeswijk; J W Mulder; P L Meenhorst; R M Hoetelmans; J M Lange; J H Beijnen Journal: Ther Drug Monit Date: 2001-12 Impact factor: 3.681
Authors: P T Nieuwkerk; M A Sprangers; D M Burger; R M Hoetelmans; P W Hugen; S A Danner; M E van Der Ende; M M Schneider; G Schrey; P L Meenhorst; H G Sprenger; R H Kauffmann; M Jambroes; M A Chesney; F de Wolf; J M Lange Journal: Arch Intern Med Date: 2001-09-10
Authors: E Martínez; J L Blanco; J A Arnaiz; J B Pérez-Cuevas; A Mocroft; A Cruceta; M A Marcos; A Milinkovic; M A García-Viejo; J Mallolas; X Carné; A Phillips; J M Gatell Journal: AIDS Date: 2001-07-06 Impact factor: 4.177
Authors: R M Hoetelmans; M H Reijers; G J Weverling; R W ten Kate; F W Wit; J W Mulder; H M Weigel; P H Frissen; M Roos; S Jurriaans; H Schuitemaker; F de Wolf; J H Beijnen; J M Lange Journal: AIDS Date: 1998-07-30 Impact factor: 4.177
Authors: David M Burger; Patricia W H Hugen; Rob E Aarnoutse; Richard M W Hoetelmans; Marielle Jambroes; Pythia T Nieuwkerk; Gerrit Schreij; Margriet M E Schneider; Marchina E van der Ende; Joep M A Lange Journal: Ther Drug Monit Date: 2003-02 Impact factor: 3.681
Authors: D Havlir; S H Cheeseman; M McLaughlin; R Murphy; A Erice; S A Spector; T C Greenough; J L Sullivan; D Hall; M Myers Journal: J Infect Dis Date: 1995-03 Impact factor: 5.226
Authors: Andrzej Bienczak; Paolo Denti; Adrian Cook; Lubbe Wiesner; Veronica Mulenga; Cissy Kityo; Addy Kekitiinwa; Diana M Gibb; David Burger; Ann S Walker; Helen McIlleron Journal: AIDS Date: 2017-04-24 Impact factor: 4.177
Authors: Frantz Foissac; Jörn Blume; Jean-Marc Tréluyer; Thorkild Tylleskär; Chipepo Kankasa; Nicolas Meda; James K Tumwine; Mandisa Singata-Madliki; Kim Harper; Silvia M Illamola; Naïm Bouazza; Nicolas Nagot; Philippe Van de Perre; Stéphane Blanche; Déborah Hirt Journal: Antimicrob Agents Chemother Date: 2017-01-24 Impact factor: 5.191
Authors: Fenglei Huang; Michael Koenen-Bergmann; Thomas R Macgregor; Arne Ring; Susan Hattox; Patrick Robinson Journal: Antimicrob Agents Chemother Date: 2008-09-29 Impact factor: 5.191
Authors: Edward P Acosta; Kay L Limoli; Lan Trinh; Neil T Parkin; Jennifer R King; Jodi M Weidler; Ighovwerha Ofotokun; Christos J Petropoulos Journal: Antimicrob Agents Chemother Date: 2012-09-10 Impact factor: 5.191